Skip to content

Impact of immunomodulation on the prognosis of acute ischemic stroke patients with endovascular thrombectomy

Impact of immunomodulation on the prognosis of acute ischemic stroke patients with endovascular thrombectomy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072507
Enrollment
Unknown
Registered
2023-06-15
Start date
2022-04-11
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Good vascular recanalization group:N/A
Poor vascular recanalization group:N/A

Sponsors

Affiliated Beijing Chaoyang Hospital of Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age 18-80 years old; 2) Acute ischemic stroke diagnosed by clinical manifestations, cranial computed tomography, angiography (CT, CTA), and interventional angiography, and the infarct site is anterior circulation artery; 3) Meet the requirements of "China Guidelines for Early Endovascular Interventional Diagnosis and Treatment of Acute Ischemic Stroke in China"; 4) Informed consent of the patient himself or his legal representative.

Exclusion criteria

Exclusion criteria: 1) Venous blood glucose is lower than 2.7 or higher than 22.2mmol/L; 2) Severe bleeding tendency (meet any of the following): peripheral blood platelet count 50s, international normalized ratio (INR)>3.0; 3) Severe hepatic or renal insufficiency: Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal; serum creatinine > 1.5 times the upper limit of normal; 4) Those who have experienced infarction or bleeding in the responsible vessel watershed within the past 6 weeks; 5) Those who have any form of autoimmune disease, long-term use of immunosuppressive agents or glucocorticoid therapy; 6) Patients with confirmed active infectious diseases; 7) Pregnant or lactating women; 8) The patient/legal representative has poor compliance as judged by the patient's attending physician, or the patient/legal representative refuses to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
90 day mRS;

Secondary

MeasureTime frame
symptomatic intracranial hemorrhage;asymptomatic intracranial hemorrhage;Cerebral herniation;

Countries

China

Contacts

Public ContactYang Wang

Affiliated Beijing Chaoyang Hospital of Capital Medical University

15110299052@163.com+86 151 1029 9052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026